Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study Erik Thunnissen, MD, PhD, Masayuki.

Slides:

Advertisements

Similar presentations

A RETROSPECTIVE ANALYSIS OF FREQUENCY OF ALK GENE

Advertisements

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Neal I. Lindeman, Philip T. Cagle, Mary Beth.

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart William D. Travis, MD, Elisabeth Brambilla,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Ugonna N. Ihekweazu, BS, William D. Travis, MD, Raja M. Flores, MD

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study.

The 2015 World Health Organization Classification of Lung Tumors

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Neal I. Lindeman,

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Neal I. Lindeman,

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ming-Sound Tsao, MD, FRCPC, William D

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart William D. Travis, MD, Elisabeth Brambilla,

Robert Pirker, MD, Felix J. F. Herth, MD, PhD, FCCP, Keith M

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non– Small-Cell Lung Cancer Josette Biya, MD, Caroline Caramella, MD, Colin.

Frank Detterbeck, MD Journal of Thoracic Oncology

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis Xin Luo, MD, Xiao Zang, BS, Lin Yang, MD, Junzhou Huang, PhD,

Histologic Transformation in NSCLC with PD-1 therapy

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Michael A. den Bakker, MD, PhD, Anja C

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Analysis of Tumor Markers in the Cytological Fluid Obtained from Computed Tomography-Guided Needle Aspiration Biopsy for the Diagnosis of Non-small Cell.

Mitotic Inhibitors Journal of Thoracic Oncology

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel.

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Carlie S. Sigel, MD, Andre L. Moreira, MD, PhD, William D

The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho- Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM.

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

In This Issue Journal of Thoracic Oncology

Genetic Changes in Squamous Cell Lung Cancer: A Review

Joan J. Ryoo, MD, MSHS, Jennifer L. Malin, MD, PhD, Diana L

Transcutaneous Computed Bioconductance Measurement in Lung Cancer: A Treatment Enabling Technology Useful for Adjunctive Risk Stratification in the Evaluation.

A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors Jules L. Derks, MD, Robert Jan.

S-1 Treatment for Chemorefractory Thymic Carcinoma

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

Neuronatin Expression and Its Clinicopathological Significance in Pulmonary Non-small Cell Carcinoma Teruhito Uchihara, MD, Chigusa Okubo, MS, Ryota.

IASLC 6th Latin American Conference on Lung Cancer

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Analysis of Differentially Expressed Genes in Neuroendocrine Carcinomas of the Lung Chigusa Okubo, MS, Yuko Minami, MD, Ryota Tanaka, MD, Teruhito Uchihara,

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

A Review of First-Line Treatment for Small-cell Lung Cancer

Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions Mauricio Burotto, MD, Anish Thomas, MD, Deepa Subramaniam,

Presentation transcript:

Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study Erik Thunnissen, MD, PhD, Masayuki Noguchi, MD, Seena Aisner, MD, Mary Beth Beasley, MD, Elisabeth Brambilla, MD, PhD, Lucian R. Chirieac, MD, Jin-Haeng Chung, MD, PhD, Sanja Dacic, MD, Kim R. Geisinger, MD, Fred R. Hirsch, MD, PhD, Yuichi Ishikawa, MD, PhD, Keith M. Kerr, MD, PhD, Sylvie Lantejoul, MD, PhD, Yoshiro Matsuno, MD, Yuko Minami, MD, Andre L. Moreira, MD, Giuseppe Pelosi, MD, Iver Petersen, MD, PhD, Victor Roggli, MD, William D. Travis, MD, Ignacio Wistuba, MD, Yasushi Yatabe, MD, PhD, Rafal Dziadziuszko, MD, PhD, Birgit Witte, PhD, Ming-Sound Tsao, MD, FRCPC, Andrew G. Nicholson, DM Journal of Thoracic Oncology Volume 9, Issue 9, Pages 1354-1362 (September 2014) DOI: 10.1097/JTO.0000000000000264 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A flow chart for the application of histological criteria in poorly differentiated SqCC based on the WHO classification 2004.1 HPF, high power field; NUT, NUT midline carcinoma, family member 1 (NUTM1); SqCC, squamous cell carcinoma; WHO, World Health Organization. Journal of Thoracic Oncology 2014 9, 1354-1362DOI: (10.1097/JTO.0000000000000264) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Example of consensus squamous cell carcinoma. A, Overview, ×20 (B), example of spindle cells in diffuse architecture (no nests or fields) (C), consensus score for lymphocytic infiltrate between the tumor cells (D), For palisading, no consensus was obtained: 25% of the pathologists called this palisading (E), detailed images with around the centered cell in at least part of the perimeter features of intercellular bridges (F, G), detailed images with three examples of intercellular gaps (called by most pathologists) (H–J), example of intracytoplasmic vacuole (arrow, consensus by all the pathologists) (K). Journal of Thoracic Oncology 2014 9, 1354-1362DOI: (10.1097/JTO.0000000000000264) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions